We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC: FDA Biologics Naming Proposal Could Hurt Biosimilar Markets
FTC: FDA Biologics Naming Proposal Could Hurt Biosimilar Markets
The FTC is telling the FDA that its proposal to add four-letter suffixes to nonproprietary names for biosimilars and other biological products could be bad for business.